沙利度胺联合替吉奥、奥沙利铂化疗方案对晚期胃癌患者治疗效果评价

目的 探讨沙利度胺联合替吉奥、奥沙利铂(SOX)化疗方案对晚期胃癌患者肿瘤标志物水平及不良反应的影响。方法 选取某医院2015年8月—2018年8月收治的50例晚期胃癌患者,根据随机数表法分为对照组和观察组,每组各25例。对照组给予沙利度胺药物治疗,观察组在此基础上加用SOX化疗方案治疗。两组均连续治疗4周期,每周期为21 d。比较两组患者血清肿瘤标志物肿瘤坏死因子α(TNF-α)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]变化水平及不良反应(恶心呕吐、周围神经毒性、血小板减少)发生率。结果 治疗后,观察组患者TNF-α、CEA、CA19-9水平为(211.46±15.32)pg/mL、(5.11±0.98)U/mL、(43.01±11.58)U/mL,均低于对照组(270.12±16.89)pg/mL、(8.54±1.61)U/mL、(55.68±18.76)U/mL,差异有统计学意义(t=12.862、9.099、2.874,P值均<0.01);观察组患者不良反应发生率(16.00%)与对照组(28.00%)相比差异无统计学意义(χ2=1.049,P=0.306)。结论 沙利度胺联合SOX化疗方案可有效降低晚期胃癌患者TNF-α、CEA、CA19-9水平,且用药安全。

Therapeutic efficiency of thalidomide combined with SOX chemotherapy in patients with advanced gastric cancer

Objective To investigate the effect of thalidomide combined with SOX chemotherapy on tumor markers and adverse reactions in patients with advanced gastric cancer. Methods From August 2015 to August 2018, 50 patients with advanced gastric cancer were randomly divided into a control group (n=25) and a trial group (n=25). The control group was treated with thalidomide, and the trial group was treated with SOX chemotherapy regimen (tigio, oxaliplatin) on the basis of the treatment of the control group. Both groups were treated continuously for 4 cycles, and each cycle for 21 days. The levels of serum tumor markers were compared between the two groups. The incidence rates of adverse reactions (nausea and vomiting, peripheral neurotoxicity, and thrombopenia) were also compared between the two groups. Results After the treatment, the levels of TNF- α, CEA, and CA19-9 in the trial group were (211.46±15.32) pg/ml, (5.11±0.98) U/ml, and (43.01±11.58) U/ml respectively, which were lower than those in the control group , and the differences were statistically significant (t=12.862, 9.099, 2.874 respectively and all P ≤ 0.01). but there was no significant difference in the incidence rates of adverse reactions between the trial group (16.00%) and the control group (28.00%) (χ2=1.049, P=0.306). Conclusion Thalidomide combined with SOX chemotherapy can effectively reduce the levels of TNF-α and CEA, CA19-9 in the patients with advanced gastric cancer, and the therapy is safe.